Astellas Announces FDA Approval of ASTAGRAF XL(TM) (tacrolimus extended ... MarketWatch The two primary, randomized, comparative phase 3 clinical studies to support FDA approval enrolled 1,093 patients (545 on tacrolimus extended-release) in the U.S., Europe, Canada, South America, Australia and South Africa. Astellas was granted ... |
